Products from BPS Bioscience require a minimum order value above 400€
Application: Use as positive control in the development of anti-CD19 CAR- Gamma Delta T Cells (δ2).Screen modulators of anti-CD19 CAR-Gamma Delta T Cell (δ2) cytotoxicity.Design and optimize co-culture cytotoxicity assays for anti-CD19 CAR-Gamma Delta T cell (δ2) specific evaluation.
Background: T lymphocytes are composed of two subpopulations: αβ T cells and γδ T cells. They are distinguished by the expression of either a TCR or a γδ TCR, respectively. αβ T cells are the predominant subset of T cells in peripheral blood and recognize antigens presented by MHC (major histocompatibility complex) molecules. γδ T cells are less abundant and recognize antigens independently of MHC presentation. While both αβ T cells and γδ T cells contribute to cell cytotoxicity through distinct mechanisms to target and eliminate infected or abnormal cells, γδ T cells have a lower risk of causing GvHD (Graft-versus-Host Disease) when injected into humans and have demonstrated cytotoxicity against a wide range of tumor types. γδ TCRs are cell type specific, with Vγ9Vδ2 being present in T cells and corresponding to about 5% of the T cell population in blood. Vγ9Vδ2 T cells are involved mostly in immune responses to pathogens and long-term modulation of inflammation, and can recognize non-peptide phosphor-antigens, alkylamines and synthetic amino-bisphosphonates. Vγ9Vδ2 T cells are being studied for the treatment of solid tumors and hematological disorders and are becoming a highly promising cancer therapy. Further studies on how best to utilize Vγ9Vδ2 T cells, and methods to enhance their presence, will open new therapeutic avenues for cancer and infections.
Description: Anti-CD19 CAR-Gamma Delta T Cells (δ2) are produced by high-titer lentiviral transduction of human peripheral blood gamma delta 2 (δ2) T cells using the Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ; SIN Vector, #78601). These ready-to use CAR (chimeric antigen receptor)-Gamma Delta T cells express an anti-CD19 CAR consisting of the ScFv (Single chain fragment variable) of anti-CD19 (clone FMC63) linked to a 2nd generation CAR containing the CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains (Figure 1).These CAR-T cells have been validated using flow cytometry (to determine the CAR expression) and co-culture cytotoxicity assays.Figure 1: Construct diagram showing components of the anti-CD19 CAR expressed in Anti-CD19 CAR- Gamma Delta T Cells (δ2).
Mycoplasma Testing: The cells have been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of cryopreservation solution
Target: CD19
Uniprot: P15391
Warnings: Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate biological safety level 2 precautions should be used.
Biosafety Level: BSL-1
References: Allison T. and Garboczi D., 2002 Molecular Immunology 38 (14): 1051-1061.Sawaisorn P., et al., 2024 Scientific Reports 14: 1291.
English
Deutsch
